Ten-Year Follow-Up of Taliglucerase Alfa in Type 1 Gaucher Disease: Real-World Evidence from Albania
Authors:
- Paskal CullufiPCPaskal Cullufi
- Virtut VelmishiVVVirtut Velmishi
- Erjon TrojaETErjon Troja
- Sonila TomoriSTSonila Tomori
- Ermira DervishiEDErmira Dervishi
- Gladiola HoxhaGHGladiola Hoxha
- Marjeta TankaMTMarjeta Tanka
- Polikron PulluqiPPPolikron Pulluqi
- Adela PerollaAdela Perolla
- Entela BashaEBEntela Basha
- Arben IvanajAIArben Ivanaj
- Eda JazexhiuEJEda Jazexhiu
Open Access
- 3 October 2025
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (19) , 7015
Abstract
Background/Objectives: Gaucher disease type 1 is an autosomal recessive lysosomal storage disorder caused by pathogenic variants in the GBA1 gene. Although enzyme replacement therapy has improved patient outcomes, there is limited long-term real-world data on taliglucerase alfa. This study aimed to evaluate the long-term efficacy and safety of taliglucerase alfa in both treatment-naïve and previously treated patients with Gaucher disease type 1 over a 10-year period. Methods: This prospective, single-centre cohort study involved 29 patients (13 treatment-naïve and 16 previously treated with imiglucerase) who received taliglucerase alfa from 2015 to 2024. Clinical, hematological, visceral, skeletal, and biochemical parameters were assessed at baseline and at 12, 60, and 120 months. Biomarkers included chitotriosidase and glucosylsphingosine. Safety was evaluated through adverse event reporting and anti-drug antibody testing. Results: Hemoglobin and platelet counts improved or remained stable in all patients. By 60 months, liver volume had normalised in treatment-naïve patients (mean reduction: 23.1%), while spleen volume had decreased by up to 47.3%. Lyso-Gb1 levels decreased by 86.1% in patients who had not previously received treatment and by 59.5% overall, with a strong correlation to adherence. Bone mineral density improved in most cases. 137 adverse events were reported, 24% of which were mild infusion-related reactions. Anti-drug antibody developed in two patients, including one with a reduced therapeutic response. Conclusions: Taliglucerase alfa offers sustained long-term clinical, hematological and biochemical benefits in both treatment-naïve and previously treated Gaucher disease type 1 patients, with a favorable safety profile. Glucosylsphingosine proved to be a highly sensitive biomarker for monitoring therapeutic efficacy and detecting treatment response.Keywords
This publication has 42 references indexed in Scilit:
- The Diagnosis and Therapy of Osteoporosis in Gaucher DiseaseCalcified Tissue International, 2025
- Expanding the clinical utility of glucosylsphingosine for Gaucher diseaseJournal of Inherited Metabolic Disease, 2019
- Long-term efficacy and safety results of taliglucerase alfa through 5 years in adult treatment-naïve patients with Gaucher diseaseBlood Cells, Molecules, and Diseases, 2019
- Gaucher Disease in Bone: From Pathophysiology to PracticeJournal of Bone and Mineral Research, 2019
- Delayed Infusion Reactions to Enzyme Replacement Therapies2016
- Glucosylsphingosine is a key biomarker of Gaucher diseaseAmerican Journal of Hematology, 2016
- Enzyme replacement therapy with taliglucerase alfa: 36‐month safety and efficacy results in adult patients with Gaucher disease previously treated with imigluceraseAmerican Journal of Hematology, 2016
- Long‐term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment‐naïve patients with Gaucher diseaseAmerican Journal of Hematology, 2016
- Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher diseaseBlood Cells, Molecules, and Diseases, 2015
- Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher diseaseBlood Cells, Molecules, and Diseases, 2013